I-OPen: Inferior Outcomes of Penta-refractory Compared to Penta-exposed Multiple Myeloma Patients

Overview

Journal Blood Cancer J

Date 2022 Sep 23

PMID 36151090

Authors

Sarvarinder K Gill

Rashmi Unawane

Shuqi Wang

Jaeil Ahn

Adolfo Aleman

David S Siegel

David H Vesole

Harsh Parmar

Pooja Phull

Noa Biran

Affiliations

Soon will be listed here.

Citing Articles

Advancements in the Treatment of Multiple Myeloma.

Zavaleta-Monestel E, Quesada-Villasenor R, Barrantes-Lopez M, Arguedas-Chacon S, Campos-Hernandez J, Rojas-Chinchilla C Cureus. 2025; 16(12):e74970.

PMID: 39744254 PMC: 11691229. DOI: 10.7759/cureus.74970.

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.

Parrondo R, Ailawadhi S, Cerchione C Front Oncol. 2024; 14:1394048.

PMID: 38660139 PMC: 11039948. DOI: 10.3389/fonc.2024.1394048.

Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma.

Hartley-Brown M, Mo C, Nadeem O, Midha S, Laubach J, Richardson P Cancers (Basel). 2024; 16(6).

PMID: 38539501 PMC: 10969776. DOI: 10.3390/cancers16061166.

Talquetamab in multiple myeloma.

Liu L, Krishnan A Haematologica. 2023; 109(3):718-724.

PMID: 37855056 PMC: 10905093. DOI: 10.3324/haematol.2023.283931.

Selinexor: Targeting a novel pathway in multiple myeloma.

Mo C, Yee A, Midha S, Hartley-Brown M, Nadeem O, ODonnell E EJHaem. 2023; 4(3):792-810.

PMID: 37601856 PMC: 10435704. DOI: 10.1002/jha2.709.

References

Kumar S, Rajkumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F . Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2007; 111(5):2516-20. PMC: 2254544. DOI: 10.1182/blood-2007-10-116129. View

Egan J, Shi C, Tembe W, Christoforides A, Kurdoglu A, Sinari S . Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012; 120(5):1060-6. PMC: 3412329. DOI: 10.1182/blood-2012-01-405977. View

Gandhi U, Cornell R, Lakshman A, Gahvari Z, McGehee E, Jagosky M . Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019; 33(9):2266-2275. PMC: 6820050. DOI: 10.1038/s41375-019-0435-7. View

Keats J, Chesi M, Egan J, Garbitt V, Palmer S, Braggio E . Clonal competition with alternating dominance in multiple myeloma. Blood. 2012; 120(5):1067-76. PMC: 3412330. DOI: 10.1182/blood-2012-01-405985. View

Moreau P, Attal M, Facon T . Frontline therapy of multiple myeloma. Blood. 2015; 125(20):3076-84. DOI: 10.1182/blood-2014-09-568915. View

Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A . Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol. 2020; 96(1):E5-E8. DOI: 10.1002/ajh.26010. View

Lokhorst H, Plesner T, Laubach J, Nahi H, Gimsing P, Hansson M . Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015; 373(13):1207-19. DOI: 10.1056/NEJMoa1506348. View

Lakshman A, Abeykoon J, Kumar S, Rajkumar S, Dingli D, Buadi F . Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. Am J Hematol. 2017; 92(11):1146-1155. DOI: 10.1002/ajh.24883. View

Mateos M, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M . LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022; 36(5):1371-1376. PMC: 9061296. DOI: 10.1038/s41375-022-01531-2. View

10.

Durie B, Harousseau J, Miguel J, Blade J, Barlogie B, Anderson K . International uniform response criteria for multiple myeloma. Leukemia. 2006; 20(9):1467-73. DOI: 10.1038/sj.leu.2404284. View

11.

Rajkumar S, Harousseau J, Durie B, Anderson K, Dimopoulos M, Kyle R . Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18):4691-5. PMC: 3710442. DOI: 10.1182/blood-2010-10-299487. View

12.

Kumar S, Dispenzieri A, Lacy M, Gertz M, Buadi F, Pandey S . Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2013; 28(5):1122-8. PMC: 4000285. DOI: 10.1038/leu.2013.313. View

13.

Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson K . Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016; 127(24):2955-62. PMC: 4920674. DOI: 10.1182/blood-2016-01-631200. View

14.

Walker B, Boyle E, Wardell C, Murison A, Begum D, Dahir N . Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J Clin Oncol. 2015; 33(33):3911-20. PMC: 6485456. DOI: 10.1200/JCO.2014.59.1503. View

15.

Duan D, Wang K, Wei C, Feng D, Liu Y, He Q . The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma. Front Immunol. 2021; 12:609421. PMC: 7985831. DOI: 10.3389/fimmu.2021.609421. View